SG11201810019RA - Methods of human leukocyte antigen typing - Google Patents

Methods of human leukocyte antigen typing

Info

Publication number
SG11201810019RA
SG11201810019RA SG11201810019RA SG11201810019RA SG11201810019RA SG 11201810019R A SG11201810019R A SG 11201810019RA SG 11201810019R A SG11201810019R A SG 11201810019RA SG 11201810019R A SG11201810019R A SG 11201810019RA SG 11201810019R A SG11201810019R A SG 11201810019RA
Authority
SG
Singapore
Prior art keywords
international
methods
applicant
pct
rule
Prior art date
Application number
SG11201810019RA
Inventor
Chao Xie
Original Assignee
Human Longevity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Longevity Inc filed Critical Human Longevity Inc
Publication of SG11201810019RA publication Critical patent/SG11201810019RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) WIPO I PCT iii 11111111111111111111111111111111111111111111111111111111111011111111111111111111111111 (10) International Publication Number WO 2017/205678 Al (51) International Patent Classification: C12Q 1/68 (2006.01) GOOF 19/22 (2011.01) (21) International Application Number: PCT/US2017/034556 (22) International Filing Date: 25 May 2017 (25.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/342,817 27 May 2016 (27.05.2016) US (71) Applicant: HUMAN LONGEVITY, INC. [US/US]; 4570 Executive Drive, San Diego, California 92121 (US). (72) Inventor: XIE, Chao; c/o Human Longevity, Inc., 4570 Declarations under Rule 4.17: Executive Drive, San Diego, California 92121 (US). (74) Agent: BURKETTE, Scott L. et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: METHODS OF HUMAN LEUKOCYTE ANTIGEN TYPING (57) : Described herein are methods, systems, and media for HLA typing an indi- ig. 7 vidual from nucleic acid or protein sequences. The methodology disclosed herein represents significant improvements over current methods of HLA typing. 703 704 705 la alai allele sett • • • slain oar. PvMr W O 20 17 / 205 67 8 Al 707 708 709
SG11201810019RA 2016-05-27 2017-05-25 Methods of human leukocyte antigen typing SG11201810019RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342817P 2016-05-27 2016-05-27
PCT/US2017/034556 WO2017205678A1 (en) 2016-05-27 2017-05-25 Methods of human leukocyte antigen typing

Publications (1)

Publication Number Publication Date
SG11201810019RA true SG11201810019RA (en) 2018-12-28

Family

ID=60411879

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810019RA SG11201810019RA (en) 2016-05-27 2017-05-25 Methods of human leukocyte antigen typing

Country Status (8)

Country Link
US (2) US20170342479A1 (en)
EP (1) EP3464635A4 (en)
JP (1) JP2019524055A (en)
KR (1) KR20190001953A (en)
CN (1) CN109477143A (en)
CA (1) CA3022851A1 (en)
SG (1) SG11201810019RA (en)
WO (1) WO2017205678A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
CN111312332B (en) * 2020-02-13 2020-10-30 国家卫生健康委科学技术研究所 Biological information processing method and device based on HLA genes and terminal
WO2022131691A1 (en) * 2020-12-17 2022-06-23 주식회사 네오젠티씨 Method for determining type of human leukocyte antigen
KR102507088B1 (en) * 2020-12-17 2023-03-07 주식회사 네오젠티씨 Human leukocyte antigen typing method and medical personalization method through the same
KR20220087344A (en) 2020-12-17 2022-06-24 주식회사 네오젠티씨 Human leukocyte antigen typing method and medical personalization method through the same
CN113373208A (en) * 2021-07-14 2021-09-10 上海序祯达生物科技有限公司 Human leukocyte antigen typing system and method based on next generation sequencing
CN114090845B (en) * 2022-01-19 2022-04-29 首都医科大学附属北京友谊医院 Method and device for matching blood donors for blood recipients
WO2023196925A2 (en) * 2022-04-07 2023-10-12 Guardant Health, Inc. Methods and systems for allele typing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056103A2 (en) * 2013-10-15 2015-04-23 Regeneron Pharmaceuticals, Inc. High resolution allele identification
WO2015085147A1 (en) * 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data

Also Published As

Publication number Publication date
WO2017205678A9 (en) 2018-12-27
KR20190001953A (en) 2019-01-07
CA3022851A1 (en) 2017-11-30
WO2017205678A1 (en) 2017-11-30
JP2019524055A (en) 2019-09-05
EP3464635A4 (en) 2020-01-22
CN109477143A (en) 2019-03-15
US20170342479A1 (en) 2017-11-30
EP3464635A1 (en) 2019-04-10
US20200239952A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
SG11201810019RA (en) Methods of human leukocyte antigen typing
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201808196UA (en) Neoantigens and methods of their use
SG11201909011PA (en) Niraparib compositions
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201906213UA (en) Modulating expression of polypeptides via new gene switch expression systems
SG11201901563UA (en) De novo synthesized nucleic acid libraries
SG11201907056XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201809627QA (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201807982UA (en) Substituted inhibitors of menin-mll and methods of use
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201811025VA (en) Systems and methods for automated annotation and screening of biological sequences
SG11202000145XA (en) Methods and systems for conditionally regulating gene expression
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis